bloomberg.com web signal

MegaRobo raises ~$200M from Oman fund for AI lab robotics

TL;DR

  • Beijing's MegaRobo raised close to $200M with Oman Investment Authority and CMB International as new backers, taking total funding to roughly $600M.
  • Its AI robotics automate drug screening and run precision sensing on semiconductor and display production lines, serving more than 1,200 customers.
  • About 80% of revenue is still domestic; MegaRobo filed for a Hong Kong IPO in mid-2025 and remains in the queue.

Beijing's MegaRobo Technologies has raised close to $200 million in a round joined by Oman's sovereign wealth fund, Bloomberg reported, taking the AI-and-robotics company's total funding to about $600 million since it was founded in 2016.

The Oman Investment Authority and CMB International were the new money; Asia Investment Capital, Granite Asia and Kai-Fu Lee's Sinovation Ventures reupped. DealStreetAsia says MegaRobo's systems automate laboratory workflows for drug screening and run high-precision sensing on semiconductor, optical interconnect and display production lines, with more than 1,200 pharmaceutical firms, biotech companies and academic institutions as customers. About 80% of revenue still comes from China.

Founder and CEO Daniel Huang told Bloomberg the company sees "a great deal" of overseas growth opportunity, particularly across Belt and Road markets. In a separate statement, Huang said autonomous AI agents can "lower research costs and shorten the path from laboratory discovery to market."

MegaRobo filed for a Hong Kong listing in mid-2025 and remains in the IPO queue. A June 2022 Series C co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia had already pushed its valuation above $1 billion. Proceeds from the new round will fund research and development and global expansion, the company says.